Data Provided by Refinitiv. Minimum 15 minutes delayed.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational UpdatesAug 08, 2022
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLCJul 27, 2022
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer TherapiesJun 24, 2022